Sucrose stabilization of Respiratory Syncytial Virus (RSV) during nebulization and experimental infection

BMC Research Notes

Mark R Ackermann¹  Rachel J Derscheid¹  Shannon J Hostetter¹  Jack M Gallup¹  Albert van Geelen¹  Drew D Grosz¹ 

[1] Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State University, 1600 S. 16th Street, Ames, IA 50011-1250, USA

关键词: Sucrose;    Nebulization;    RSV;    Respiratory Syncytial Virus;   

Others  :  1134228
DOI  :  10.1186/1756-0500-7-158

 received in 2013-07-19, accepted in 2014-03-12,  发布年份 2014

【 摘 要 】

Background

Respiratory syncytial virus (RSV) is a common respiratory pathogen that can cause severe pneumonia. In vivo studies of RSV can be difficult due to variation in viral infection and disease severity in some animal models. Factors that may contribute to the variation are decreases in viral titer due to preparation and storage and method of virus administration. Nebulization is one method of RSV administration that provides even distribution of virus to all lung lobes; however, the exact quantity of the virus killed by nebulization is not defined. To test the hypothesis that sucrose enhances RSV stability and infectivity, a series of in vitro experiments were conducted with RSV strain Memphis 37 stored at varying concentrations (0%, 3%, 5%, 8%, 10%, 15%, and 20%) of sucrose as a possible cryo- and nebulization protectant. The optimal in vitro concentration was then assessed in vivo in a lamb model.

Methods

Prior to titering the virus on HEp-2 cells, the various virus solutions were subjected to one freeze-thaw cycle and one nebulization cycle. Forty-eight hours after viral plating, infectious foci were detected and counted using immunofluorescent imaging. Titers were determined after freeze-thaw and after freeze-thaw followed by nebulization, then compared to the stock titers (before freezing) as well as to one another to determine the loss of infectivity. To further test this in vivo, lambs 2 to 3-days-old were infected via nebulization with RSV using inoculate containing either 20% sucrose or no sucrose followed by assessments of infection severity.

Results

Nebulization of virus in 0% sucrose resulted in a 0.580 log reduction in infectivity while virus in 20% sucrose exhibited a 0.297 log reduction. In vivo studies demonstrated that 20% sucrose enhanced RSV lesions and antigen distribution.

Conclusions

The data suggests that both nebulization and freeze-thawing of RSV in the absence of sucrose cause unacceptable losses in viral infectivity and that sucrose acts as a RSV protectant in both regards.

【 授权许可】

   
2014 Grosz et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões AF, Rudan I, Weber MW, Campbell H: Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
• [2]WHO: Acute respiratory infections (update September 2009). 2009 09/09 [cited 2013]. http://www.who.int/vaccine_research/diseases/ari/en/index2.html webcite
• [3]Collins PL, Melero JA: Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011, 162:80-99.
• [4]Garcia CG, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O, Mejias A: Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010, 126:e1453-e1460.
• [5]Hon KL, Leung TF, Cheng WY, Ko NM, Tang WK, Wong WW, Yeung WH, Chan PK: Respiratory syncytial virus morbidity, premorbid factors, seasonality, and implications for prophylaxis. J Crit Care 2012, 5:464-468.
• [6]Sommer C, Resch B, Simoes EA: Risk factors for severe respiratory syncytial virus lower respiratory tract infection. J Open Microbiol 2012, 5:144-154.
• [7]Welliver RC, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB: Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 2010, 26:2175-2181.
• [8]Abed Y, Boivin G: Treatment of respiratory virus infections. Antiviral Res 2006, 70:1-16.
• [9]Empey KM, Peebles RS Jr, Kolls JK: Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010, 50:1258-1267.
• [10]Bem RA, Domachowske JB, Rosenberg HF: Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 2011, 301:L148-L156.
• [11]Derscheid RJ, Ackermann MR: Perinatal lamb model of respiratory syncytial virus (RSV) infection. Viruses 2012, 4:2359-2378.
• [12]Law TJ, Hull RN: The stabilizing effect of sucrose upon respiratory syncytial virus infectivity. Proc Soc Exp Biol Med 1968, 128:515-518.
• [13]Howell CL, Miller MJ: Effect of sucrose phosphate and sorbitol on infectivity of enveloped viruses during storage. J Clin Microbiol 1983, 18:658-662.
• [14]Gupta CK, Leszczynski J, Gupta RK, Siber GR: Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 1996, 15:1417-1420.
• [15]Sow FB, Gallup JM, Krishnan S, Patera AC, Suzich J, Ackermann MR: Respiratory syncytial virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs. Respir Res 2011, 12(1):106. BioMed Central Full Text
• [16]Sow FB, Gallup JM, Olivier A, Krishnan S, Patera AC, Suzich J, Ackermann MR: Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs. Am J Physiol Lung Cell Mol Physiol 2011, 300:L12-L24.
• [17]Olivier A, Gallup JM, de Macedo MM, Varga SM, Ackermann MR: Human respiratory syncytial virus A2 strain replicates and induces innate immune responses by respiratory epithelia of neonatal lambs. Int J Exp Pathol 2009, 90:431-438.
• [18]Olivier A, Gallup JM, van Geelen A, Ackermann MR: Exogenous administration of vascular endothelial growth factor prior to human respiratory syncytial virus A2 infection reduces pulmonary pathology in neonatal lambs and alters epithelial innate immune responses. Exp Lung Res 2011, 37:131-143.
• [19]Fischer AJ, Lennemann NJ, Krishnamurthy S, Pocza P, Durairaj L, Launspack JL, Rhein BA, Wohlford-Lenane C, Lorentzen D, Banfi B, McCray PB Jr: Enhancement of respiratory mucosal antiviral defenses by the oxidation of iodide. Am J Respir Cell Mol Biol 2011, 45:874-881.
• [20]Gallup JM, Ackermann MR: Addressing fluorogenic real-time qPCR inhibition using the novel custom Excel file system ‘FocusField2-6GallupqPCRSet-upTool-001’ to attain consistently high fidelity qPCR reactions. Biol Proced Online 2006, 8(1):87-155. PMCID: 1592462
• [21]Gallup JM, Ackermann MR: The ‘PREXCEL-Q Method’ for qPCR. Int J Biomed Sci 2008, 4:100-120.
• [22]Gallup JM, Kawashima K, Lucero G, Ackermann MR: New quick method for isolating RNA from laser captured cells stained by immunofluorescent immunochemistry; RNA suitable for direct use in fluorogenic TaqMan one-step real-time RT-PCR. Biol Proced Online 2005, 7(1):70-92.
• [23]Kawashima K, Meyerholz DK, Gallup JM, Grubor B, Lazic T, Lehmkuhl HD, Ackermann MR: Differential expression of ovine innate immune genes by preterm and neonatal lung epithelia infected with respiratory syncytial virus. Viral Immunol 2006, 19:316-323.